George Golumbeski, Ph.D.
Member
George Golumbeski has more than 30 years of experience in the biotechnology industry. He is currently focused on new company creation and stewardship. He is a partner at DROIA Ventures and serves as an independent director on several young companies (Sage Therapeutics, Shattuck Labs, Chroma Medicine, and Peptone).
Dr. Golumbeski is best known for his work at Celgene where he served as Executive Vice President of Business Development. During his tenure at Celgene, George developed new models for corporate collaborations, and led a business development effort that saw Celgene become “Partner of Choice” according to Boston Consulting Group Survey data.
Dr. Golumbeski was previously Vice President of Business Development, Licensing and Strategy at Novartis. Prior to Novartis, he was Vice President of R&D Business Development at Elan and Vice President of Corporate Development at Schwarz Pharma, where he led CNS acquisitions worldwide.
Dr. Golumbeski holds a B.A. in Biology from the University of Virginia, a Ph.D. in Genetics from the University of Wisconsin-Madison, and he conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder.